$207 Million

Tenaya Therapeutics, Inc.

Initial Public Offering

Bookrunner, July 2021

Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. (the “Company” or “Tenaya”) is a biotechnology company looking to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of disease-modifying therapies developed using their proprietary product platforms and core internal capabilities to target defined sub-populations of patients with rare as well as highly prevalent forms of heart disease. Tenaya is developing therapies through scientific advancements in three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The Company’s most advanced product candidate is their Gene Therapy program, TN-201, a one-time adeno-associated virus-based gene therapy to address genetic hypertrophic cardiomyopathy caused by Myosin Binding Protein C3 gene mutations.